Table 4.
Fatty degeneration of liver and kidney
Group | Blank | M | E1L | E1H | E2L | E2H | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
Fatty degeneration in liver | N | N | +++ | +++ | N | N | + | N | N | + | N+ | N |
Fatty degeneration in kidney | N | N | +++ | ++ | + | N | + | + | N | + | N | N |
N, no abnormity; +, slight lesioning; ++, no remarkable lesioning; +++, remarkable lesioning. M, T2DM model; E1H and E1L, flavonoid high and low doses, respectively; E2H and E2L, stilbene glycoside high and low doses, respectively.